Adial Pharmaceuticals Inc (ADIL) Stock Price Target 2026

The average analyst price target for Adial Pharmaceuticals Inc is $18.17, 273.9% above the current price. Of 4 analysts, 4 rate it Buy. Targets range from $6 to $37.50. The latest change came on Aug 3, 2026, when Alliance Global Partners initiated coverage of Adial Pharmaceuticals Inc with a Buy rating and a $11 price target.

The Average Analyst Price Target for Adial Pharmaceuticals Inc is $18.17.

Price Target Range — 4 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$18.17Upside to Avg. PT+273.9%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Adial Pharmaceuticals Inc Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 3, 2026	Alliance Global Partners	James Molloy	Initiate	Buy	$11
Jun 15, 2026	LUCID CAPITAL MARKETS	Elemer Piros	Initiate	Buy	$6
Sep 30, 2025	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$38
Nov 14, 2024	Rodman & Renshaw	Brandon Folkes	Initiate	Buy	$200

Analyst Ratings News

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $6

LUCID CAPITAL MARKETS analyst Elemer Piros initiates coverage on Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy rating and announces Price Target of $6.

Benzinga Newsdesk

This Semtech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Avi Kapoor

PRO
Maxim Group Upgrades Adial Pharmaceuticals to Buy, Announces $1.5 Price Target

Maxim Group analyst Jason McCarthy upgrades Adial Pharmaceuticals (NASDAQ:ADIL) from Hold to Buy and announces $1.5 price target.

Benzinga Newsdesk

This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Avi Kapoor

PRO
Rodman & Renshaw Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $8

Rodman & Renshaw analyst Brandon Folkes initiates coverage on Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Watching Adial Pharmaceuticals; Traders Circulate Unconfirmed Analyst Comments Suggesting "Management Is In Advanced Discussions With A Large Pharma Partner In The Addiction Marketplace In The U.S., EU, Or Both; Buy Rating With $21 PT"

Benzinga Newsdesk